Haemokinesis (ASX:HKX) says its pending listing on the ustralian Securities Exchange (ASX) will aim to boost the support of new diagnostic platforms.
The company said it has created a point of care diagnostic platform with benefits over current laboratory testing methods and an in-lab platform.
It said it owns operations infrastructure in three countries, has 24 distributors servicing 56 countries with over 130 diagnostic systems installed globally.
"Haemokinesis aims to help healthcare professionals provide patients with the best available rapid blood testing technology ‘when every second counts’." said the company, adding, it has developed a full suite of blood group analysis products for emergency, routine, donor bank and laboratory testing environments.